Dec 16 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES UPDATE ON HEALTH CANADA FILINGS FOR MYCARE AND TRINOMIA
* HLS THERAPEUTICS INC - HEALTH CANADA APPROVES MYCARE PSYCHIATRY LAB ASSAYS FOR USE IN DIAGNOSTIC LAB SETTINGS
* HLS THERAPEUTICS INC - HEALTH CANADA ISSUED A NOTICE OF DEFICIENCY FOR TRINOMIA
* HLS THERAPEUTICS INC - MYCARE INSITE POINT-OF-CARE (POC) DEVICE IS UNDER REVIEW AND COULD BE APPROVED IN H1-2021
* HLS THERAPEUTICS - WILL BE WORKING CLOSELY WITH LICENSOR OF TRINOMIA PRODUCT TO ASSESS PATHWAY REQUIRED TO ADDRESS DEFICIENCY NOTED BY HEALTH CANADA
* HLS THERAPEUTICS - PENDING SUBMISSION FOR TRINOMIA MAY REQUIRE ADDITIONAL SCIENTIFIC INFORMATION ON SAFETY AND EFFICACY TO SUPPORT APPROVAL OF APPLICATION
* HLS THERAPEUTICS INC - HEALTH CANADA NOTED THERE IS ON-GOING STUDY USING TRINOMIA
* HLS THERAPEUTICS INC - IN INTERIM, FOCUS OF CARDIOVASCULAR FRANCHISE WILL REMAIN FIRMLY ON SUCCESS OF VASCEPA IN CANADA
* HLS THERAPEUTICS INC - HEALTH CANADA NOTED THAT "…A REGULATORY DECISION FOR TRINOMIA SHOULD AWAIT THESE STUDY RESULTS."